Terms ending in 2030
Every in-force patent on Hoffmann-La Roche Inc.'s record whose computed term ends in 2030, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 12,600,781 | Tumor-Targeted Agonistic CD28 Antigen Binding Molecules In force · High confidence | Hoffmann-La Roche Inc. | In force | High confidence | |
| US 8,268,314 | Bispecific ANTI-VEGF/ANTI-ANG-2 Antibodies In force · High confidence | Hoffmann-La Roche, Inc. | In force | High confidence | |
| US 9,073,986 | Antibodies Against Human Angiopoietin 2 In force · Medium confidence | Hoffmann-La Roche Inc. | In force | Medium confidence | |
| US 9,080,183 | Promoter In force · High confidence | Hoffmann-La Roche, Inc. | In force | High confidence | |
| US 8,614,297 | Anti-Idiotype Antibody Against an Antibody Against the Amyloid Beta Peptide In force · High confidence | Hoffmann-La Roche, Inc. | In force | High confidence | |
| US 9,663,517 | Compositions and Uses Thereof In force · High confidence | Hoffman-la Roche Inc. | In force | High confidence | |
| US 9,890,204 | Trivalent, Bispecific Antibodies In force · Medium confidence | Hoffmann-La Roche Inc. | In force | Medium confidence | |
| US 10,640,555 | Bispecific Antigen Binding Proteins In force · High confidence | Hoffmann-La Roche Inc. | In force | High confidence | |
| US 8,354,444 | Substituted PYRROLIDINE-2-Carboxamides In force · Medium confidence | F. Hoffmann-La Roche AG | In force | Medium confidence | |
| US 10,711,298 | Oligonucleotide Detection Method In force · High confidence | Axolabs GmbH | In force | High confidence | |
| 32 more term ends in 2030 · Pro | |||||
10 of 42 patents shown. Soonest term end first, then patent number.
Pro members see all 42.
38 of these are in force and held by Hoffmann-La Roche Inc..
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.